Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, FATE THERAPEUTICS, INC. reported revenue of $7M, down 51.2% year over year. Operating margin was -2222.4% and net margin -2051.1%, on a free-cash-flow margin of -1685.8% with capital expenditure at 89.6% of revenue. Every figure is computed directly from FATE's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $7M | -2222.4% | -2051.1% |
| FY2024 | $14M | -1542.6% | -1366.5% |
| FY2023 | $64M | -299.9% | -253.3% |
| FY2022 | $96M | -320.2% | -292.5% |
| FY2021 | $56M | -388.6% | -379.9% |
How does FATE compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.